Cabaletta Bio to Participate in Upcoming December Investor Conferences
Cabaletta Bio, focused on engineered T cell therapies for B cell-mediated autoimmune diseases, will participate in two investor conferences in December 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cabaletta Bio, focused on engineered T cell therapies for B cell-mediated autoimmune diseases, will participate in two investor conferences in December 2020. Steven Nichtberger, M.D., the CEO, will partake in a pre-recorded chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2 and a live discussion at the Evercore ISI 3rd Annual Virtual HealthCONx Conference on December 3. The company’s pipeline includes DSG3-CAART, which targets mucosal pemphigus vulgaris and has received FDA Fast Track Designation. Webcast replays will be accessible for 90 days on their website.
Details
News Market Reaction – CABA
The recorded move for CABA in the trading session of this news was +1.70%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in December:
- Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020: A pre-recorded fireside chat with Dr. Nichtberger is now available on the company’s website.
- Evercore ISI 3rd Annual Virtual HealthCONx Conference on Thursday, December 3, 2020: Live fireside chat with Dr. Nichtberger at 9:15 a.m. ET.
All webcasts of presentations are available on the News and Events section of the company’s website at www.cabalettabio.com. Following the presentations, a replay of the webcasts will be available on the website for 90 days.
About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTesTM phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.